Opthea Raises A$227.3M for Clinical Development

Ticker: OPTEY · Form: 6-K · Filed: Jun 12, 2024 · CIK: 1815620

Sentiment: bullish

Topics: capital-raise, biotech, clinical-development

TL;DR

Opthea just announced a massive A$227.3M raise to fund its drug pipeline - big news for biotech investors.

AI Summary

Opthea Limited announced a placement and a partially underwritten entitlement offer on June 11, 2024, aiming to raise up to approximately A$227.3 million (US$150.0 million). This capital raise is intended to fund the company's ongoing clinical development programs.

Why It Matters

This significant capital injection will allow Opthea to continue advancing its promising therapies, potentially bringing new treatments to patients with serious eye conditions.

Risk Assessment

Risk Level: medium — Biotechnology companies often carry medium risk due to the inherent uncertainties in drug development and regulatory approval processes.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of the capital raise announced by Opthea?

The capital raise is intended to fund Opthea's ongoing clinical development programs.

What is the total amount Opthea aims to raise?

Opthea aims to raise up to approximately A$227.3 million.

What is the US dollar equivalent of the capital raise?

The capital raise is equivalent to approximately US$150.0 million.

What type of offering is Opthea conducting?

Opthea is conducting a placement and a partially underwritten entitlement offer.

When was this announcement made?

The announcement was made on June 11, 2024.

Filing Stats: 160 words · 1 min read · ~1 pages · Grade level 12.1 · Accepted 2024-06-11 20:36:43

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 06/12/2024

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing